Citations

Clear

237 citation(s) found for "Veronica, N".

Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome - a Multicenter Retrospective Analysis
Ball, Somedeb , Feld, Jonathan , Haddadin, Michael , Hawkins, Hayley, Guerra, Veronica , Dworkin, Emily , Tawfiq, Reema, Dulak, Dominika, Feng, Amber , Cotte, Christina , Cohen‐Nowak, Adam , Shukla, Asmita, Winer, Eric S. , Foucar, Charles , Shallis, Rory M. , Im, Annie , Szabo, Aniko, Murthy, Guru Subramanian Guru , Abboud, Ramzi , Patel, Shyam A. , Kishtagari, Ashwin , Balasubramanian, Suresh , Abaza, Yasmin , Lin, Chenyu , Badar, Talha , Patel, Anand , Atallah, Ehab

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 3206-3206

10.1182/blood-2024-211623 Get It

Background: Hypomethylating agents (HMA) with venetoclax (VEN) have shown encouraging clinical efficacy in single arm clinical trials for patients with myelodysplastic syndrome (MDS) (Garcia JS et al. ASH 2023, Zeidan AM et al. Am J Hematol. 2023). Many centers have started utilizing HMA-VEN in the clinical management of MDS due to unmet need, pending results of the ongoing phase 3 randomized clinical trial (VERONA) using this combination. However, real world studies with large sample size investigating the use of these agents in MDS, practice patterns and clinical outcomes are lacking. Methods: This is a multicenter retrospective study of 13 US academic medical centers. We included contemporary cohorts of adults (age≥18 years) with MDS who were treated with upfront combination of HMA-VEN, upfront HMA monotherapy, or VEN added after inadequate response or progression on HMA (post-HMA failure VEN). Outcomes analyzed includes clinical response, adverse events (AE) of interest, dose administration and survival. Descriptive statistics were used for baseline characteristics. Overall survival and event free survival (EFS: progression, leukemic transformation, death as events) analysis was conducted using Kaplan-Meier method. Determinants of outcomes were analyzed using multivariable regression models. All analyses were conducted at a significance level of p<0.05. Results: Among 454 patients included, 258 patients received VEN in combination with HMA [upfront HMA-VEN (n=175), post-HMA failure VEN (n=83)] and 196 patients received HMA monotherapy. Median age was 69 (59-77) years and majority of patients had MDS with excess blasts (75%), high risk (31.9%) or very-high (41.8%) risk disease by IPSS-R, 23.7% had therapy related disease, 33% had deletion17p or TP53 mutation and 40.9% underwent allogeneic stem cell transplantation. VEN was predominantly started in outpatient setting (78.6%) with tumor lysis syndrome (TLS) prophylaxis and VEN doses ranged from 70-400mg, adjusted for concomitant antifungal drugs. Incidence of TLS was minimal (No TLS- 92.9%, lab-only TLS 6.2%, 1 pt with clinical TLS). Neutropenic fever was the main AE noted [upfront VEN-HMA (34.2%), HMA monotherapy (22.5%), post-HMA VEN (44.5%)]. In the upfront setting, response rate was significantly higher with HMA-VEN than HMA monotherapy (CR: 33% vs 12%; marrow CR: 40% vs 27%, p<.001). VEN given in the post HMA failure setting also resulted in encouraging response rates (CR 10%, marrow CR 32%). After adjusting for covariates in multivariable analysis, patients treated with HMA-VEN in the upfront setting had significantly improved event free survival as compared to HMA monotherapy (HR 0.59, HR 0.44-0.78, p<0.01), but overall survival did not reach statistical significance (overall survival HR 0.77, 95%CI 0.57-1.04, p=0.08). Conclusions: In this large multicenter retrospective analysis from US academic medical centers, we found that VEN in combination with HMA resulted in encouraging clinical outcomes and was effectively administered in the outpatient setting with minimal TLS. Infection risk management and supportive measures would be important to improve the ability to use this treatment widely, pending results of the ongoing phase 3 randomized clinical trial. Updated results with additional variables will be available at the main meeting.
A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
Dall'Olio, Lorenzo, Pleyer, Lisa , Montalban‐Bravo, Guillermo , Bazinet, Alexandre , Meggendorfer, Manja , Sauta, Elisabetta, Travaglino, Erica , Quintela, David, Jerez, Andrés , Cornejo, Elena, Martín, Paloma García, Roldán, Verónica , Suarez, Dolly Viviana Fiallo, Velasco, Estefania Cerezo, Calabuig, Marisa , Souchet, Laëtitia, Borin, Lorenza, Diral, Elisa , Vučinić, Vladan , Russo, Antonio , Tentori, Cristina Astrid , Buizza, Alessandro, Delleani, Mattia , Consagra, Angela , Kiwan, Ahmad , Ali, Najla H. Al, Sallman, David A. , Garcia-Manero, Guillermo, Follo, Matilde Y. , Maciejewski, Jaroslaw P. , Bejar, Rafael, Thol, Felicitas , Fenaux, Pierre , Haferlach, Torsten, Germing, Ulrich, Patnaik, Mrinal M. , Padron, Eric , Lanino, Luca , Hunter, Anthony M. , Gagelmann, Nico , Robin, Marie , Sala, Claudia , Dall’Olio, Daniele , Gurnari, Carmelo , Dall'Olio, Lorenzo, Wang, Yu‐Hung , Xicoy, Blanca , Shih, Lee‐Yung , Haque, Tamanna Zohra , Abdel‐Wahab, Omar , Geissler, Klaus H. , Bataller, Alex , Casetti, Ilaria Carola , Sauta, Elisabetta , Palomo, Laura , Zamora, Lurdes , Díaz‐Beyá, Marina , Pita, Alejandro Avendaño, Roldan, Veronica, Such, Esperanza , Sanz, Guillermo , Platzbecker, Anne Sophie , Castilla‐Llorente, Cristina , Bulabois, Claude‐Eric , Awada, Hussein , Bernardi, Massimo , Chiusolo, Patrizia , Curti, Antonio , Giaccone, Luisa , Onida, Francesco , Passamonti, Francesco , Bergonzi, Gregorio Maria , Voso, Maria Teresa , Hou, Hsin‐An , Chou, Wen‐Chien , Yao, Chi‐Yuan , Lin, Chien‐Chin , Tien, Hwei‐Fang , Campagna, Alessia , Ubezio, Marta , Todisco, Gabriele , Maggioni, Giulia , Asti, Gianluca , Zampini, Matteo , Riva, Elena , Ficara, Francesca , Santoro, Armando , Carota, Luciana , Sanavia, Tiziana , Rollo, Cesare , VanOudenhove, Jennifer , Fariselli, Piero , Kern, Wolfgang , Garcia‐Manero, Guillermo , Thota, Swapna , Griffiths, Elizabeth A. , Finelli, Carlo , Platzbecker, Uwe , Solé, Françesc , Díez‐Campelo, María , Bejar, Rafael , Kröger, Nicolaus , Itzykson, Raphaël , Graubert, Timothy Aaron , Fontenay, Michaëla , Zeidan, Amer M. , Komrokji, Rami S. , Santini, Valeria , Haferlach, Torsten , Germing, Ulrich , D'Amico, Saverio , Castellani, Gastone , Solary, Éric , Porta, Matteo Giovanni Della

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 1003-1003

10.1182/blood-2024-200104 Get It

Background. Study of myeloid neoplasms (MN) has been rapidly transformed by genome characterization. Gene mutations have been reported to influence disease phenotype and risk of disease progression, and the evaluation of mutational status can provide valuable insights to improve the decision-making process. In this international study, we evaluated the clinical impact of mutational screening in patients with CMML, which is characterized by significant clinical and genomic heterogeneity, including a substantial proportion of patients with poor outcomes and unmet needs. Currently, only limited molecular information has been incorporated into CMML classification and prognostication. Methods. We retrospectively collected 3182 CMML patients. We used MOSAIC, an AI-based framework for multimodal analysis in rare cancers (PMID: 38875514) to develop innovative, molecular-based tools for classification and prognostication. An independent validation of the results on 516 prospectively collected patients was performed. Results. Bayesian Networs and Hierarchical Dirichlet Processes were used to identify genomic associations and define a CMML molecular classification. We identified 11 clusters with distinct clinical and genomic features, including splicing machinery, signal transduction and tyrosine kinase pathways aberrations, and high-risk molecular signatures (i.e., AML-like and TP53 mutations). Up to 15% of patients showed clear genomic overlap with other MN. Importantly, extensive multi-color flow cytometry on T lymphocytes, NK and myeloid cells (BD FACSymphony A5 Cell Analyzer) revealed specific immunologic and inflammation signatures associated with molecular subgroups. We then integrated molecular and clinical information to build an international CMML Prognostic Scoring System (iCPSS). We assessed the performance of different statistical and AI-based methods; L1-penalized Cox Model resulted as the best performing method. Selected features included hematological parameters (WBC, Hb, PLT and marrow blasts), cytogenetic abnormalities, and mutations in 10 genes (ASXL1, DNMT3A, EZH2, NRAS, RUNX1, SETBP1, STAG2, TET2, TP53, U2AF1). By Bayesian thresholds optimization, we identified 5 risk classes (i.e., very-low, low, intermediate, high and very-high) with median overall survival (OS) ranging from 99 to 9 months (P<.001), and median leukemia-free survival (LFS) ranging from 210 to 18 months (P<.001). iCPSS provided better patient discrimination across all clinical endpoints compared to currently available prognostic tools, with a Concordance Index (CI) for OS of 0.75 versus 0.62-0.64, respectively. Notably, compared to available scoring systems, up to 40% of patients were reassigned to higher or lower risk classes by the iCPSS. External validation on an independent prospective cohort confirmed that the performance of iCPSS is superior to existing prognostic models (CI for OS 0.71 vs 0.54-0.61, respectively) To demonstrate the clinical utility of iCPSS, we focused on 753 patients who underwent allogeneic stem cell transplantation (HSCT). In multivariable analysis, iCPSS stratified the probability of OS post-HSCT (P<.001) and identified groups of patients with different probabilities of disease relapse, ranging from 9% to 62% (P<.001). We employed a clinical- and genomic-based decision support system (PMID: 38723212) to determine the optimal timing of HSCT. Preliminary analyses indicated that higher-risk patients according to iCPSS (i.e., intermediate, high, and very high) benefit from an immediate HSCT strategy. Lower-risk patients (i.e., very low and low) had life expectancy maximized with delayed HSCT. Modeling decision analysis using iCPSS compared to conventional scores, resulted in a change in transplantation policy for a significant proportion of patients (up to 25%). Conclusion. Molecular information significantly improves the classification of CMML patients, providing a basis for refining diagnostic boundaries with other MN and for a more rational inclusion of patients in clinical trials. The iCPSS demonstrated superior performance over currently available scoring systems and improved HSCT decision making process.
SOPRANO: Macitentan in patients with pulmonary hypertension following left ventricular assist device implantation
Frantz, Robert P. , Desai, Shashank , Ewald, Gregory A. , Franco, Verónica , Hage, A., LaRue, Shane , Mathier, Michael A., Mandras, Stacy A. , Park, Myung H., Wang, I‐Wen , Zolty, Ronald , Rendon, G. Gomez, Rocco, Mark A., Selej, Mona , Zhao, Carol, Schilling, Joel D , Frantz, Robert P , Horn, Evelyn M. , Ravichandran, Ashwin Kumar , Rame, J. Eduardo

Mayo Clinic

Pulmonary Circulation | December 4, 2024 | Volume: 14 | Issue: 4 | Pages: No page available

10.1002/pul2.12446 | PMID 39635465 Get It

AbstractMacitentan is a dual endothelin receptor antagonist (ERA) approved for treating pulmonary arterial hypertension (PAH). SOPRANO evaluated the efficacy and safety of macitentan versus placebo in pulmonary hypertension (PH) patients after left ventricular assist device (LVAD) implantation. SOPRANO was a phase 2, multicenter, double‐blind, randomized, placebo‐controlled, parallel‐group study. Patients with an LVAD implanted within the prior 90 days who had persistent PH (i.e., mean pulmonary arterial pressure ≥25 mmHg, pulmonary artery wedge pressure [PAWP] ≤18 mmHg, and pulmonary vascular resistance [PVR] >3 Wood units [WU]) were randomized (1:1) to macitentan 10 mg or placebo once daily for 12 weeks. The primary endpoint was change in PVR. Secondary endpoints included change in right‐heart catheterization hemodynamic variables, N‐terminal prohormone of brain natriuretic peptide levels, World Health Organization functional class, and safety/tolerability. Fifty‐seven patients were randomized to macitentan (n = 28) or placebo (n = 29). A statistically significant reduction in PVR from baseline to Week 12 was observed with macitentan versus placebo (placebo‐corrected geometric mean ratio, 0.74; 95% confidence interval, 0.58–0.94; p = .0158). No statistically significant differences were observed in secondary endpoints. In a post‐hoc analysis, 66.7% of patients receiving macitentan achieved PVR <3 WU versus 40.0% receiving placebo (p = .0383). Macitentan was generally well tolerated; adverse events were consistent with those in previous PAH studies with macitentan. In conclusion, macitentan showed promising tolerability and significantly reduced PVR in PH patients with persistently elevated PVR after LVAD implantation. ClinicalTrials. gov identifier: NCT02554903.
Evaluating the Newly Proposed ARDS Definition in Hospitalized Patients With COVID-19 Treated With High-Flow Nasal Oxygen
Olaizola, Gustavo , Raavi, Lekhya , Jonna, Sadhana , Hanson, Abby , Monzón, Verónica , Sanghavi, Devang , Isha, Shahin , Bisso, Indalecio Carboni , Jenkins, Anna , Kashyap, Rahul, Huespe, Iván

Mayo Clinic

Respiratory Care | October 29, 2024 | Volume: 70 | Issue: 2 | Pages: 119-125

10.4187/respcare.11933 | PMID 39472067 Get It

Background: The new Global definition of ARDS recently introduced a subgroup known as non-intubated ARDS. This study aimed to assess the risk of progression from noninvasive oxygen support to intubation and ARDS severity based on the S pO 2 /F IO 2 among non-intubated subjects with ARDS. Methods: This retrospective study included subjects with COVID-19 admitted to 7 hospitals (5 in the United States and 2 in Argentina) from January 2020–January 2023. Subjects meeting the new non-intubated ARDS definition (high-flow nasal cannula [HFNC] with an S pO 2 /F IO 2 ≤315 [with S pO 2 ≤97%] or a P aO 2 /F IO 2 ≤300 mm Hg while receiving ≥30 L/min O 2 via HFNC) were included. The study evaluated the proportion of subjects who progressed to intubation, severity levels using the S pO 2 /F IO 2 cutoff proposed in the new ARDS definition, and mortality. Results: Nine hundred sixty-five non-intubated subjects with ARDS were included, of whom 27% ( n = 262) progressed to meet the Berlin criteria within a median of 3 d (interquartile range 2–6). The overall mortality was 23% (95% CI 20–26) ( n = 225), and among subjects who progressed to the Berlin criteria, it was 37% (95% CI 31–43) ( n = 98). Additionally, the worst S pO 2 /F IO 2 within 1 d of ARDS diagnosis was correlated with mortality, with mortality rates of 26% (95% CI 23–30) ( n = 177) for subjects with S pO 2 /F IO 2 ≤148, 17% (95% CI 12–23) ( n = 38) for those with S pO 2 /F IO 2 between 149–234, and 16% (95% CI 8–28) ( n = 10) for subjects maintaining an S pO 2 /F IO 2 higher than 235 ( P < .001). Conclusions: The non-intubated ARDS criteria encompassed a broader spectrum of subjects with lower in-hospital mortality compared to the Berlin criteria. The S pO 2 /F IO 2 and ARDS severity cutoff proposed in the new Global ARDS definition were valuable predictors of in-hospital mortality in these subjects.
Bridging clinical informatics and implementation science to improve cancer symptom management in ambulatory oncology practices: experiences from the IMPACT consortium
McCleary, Nadine J. , Merle, James L. , Richardson, Joshua E. , Garcia, Sofia F. , Tesch, Nathan , DiMartino, Lisa , Hassett, Michael J. , Cella, David , Smith, Justin D. , Kroner, Barbara L, Ruddy, Kathryn, Yanez, Betina R. , Bian, Jessica , Dizon, Don S. , Hazard‐Jenkins, Hannah , Ahrens, Paige, Barrett, Fiona , Begnoche, Megan, Cahue, September, Caron, Kimberly, Coughlin, Ava , Cronin, Christine , Dias, Samira , Faris, Nicolas, Flores, Anne Marie, Garcia, Martha, Hodgdon, Christine, Kircher, Sheetal , Lancki, Nicola , Mai, Quan H, Norton, Wynne E. , O’Connor, Mary , Pachman, Deirdre R. , Pearson, Loretta, Podratz, Jewel, Rahman, Parvez, Redmond, Sarah , Reich, James , Richardson, Kimberly, Schaepe, Karen , Poirier-Shelton, Tiana, Silberman, Philip , Simpson, Jaclyn, Tasker, Laura, Tramontano, Angela C. , Wong, Sandra , Cella, David , Garcia, Sofia F , Bass, Michael , Cheville, Andrea , Mitchell, Sandra A , Jensen, Roxanne E. , Minteer, Sarah A. , Austin, Jessica D. , Osarogiagbon, Raymond U. , Wong, Sandra L. , Schrag, Deborah , Smith, Ashley Wilder , Kroner, Barbara L, Griffin, Joan M. , Ruddy, Kathryn J. , Ardini, Mary-Anne , Barrett, Fiona, Chlan, Linda L. , Hemming, Karla , Herrin, Jeph , Kroenke, Kurt , Lam, Veronica, Mai, Quan H, Mallow, Jennifer A. , Penedo, Frank J. , Popovic, Jennifer R. , Preiss, Liliana , Reich, James, Ridgeway, Jennifer L. , Rutten, Lila J. Finney , Scholtens, Denise M. , Tofthagen, Cindy , Tyndall, Benjamin D. , Uno, Hajime , Wehbe, Firas , Weiner, Bryan Jeffrey

Mayo Clinic

JAMIA Open | September 5, 2024 | Volume: 7 | Issue: 3 | Pages: No page available

10.1093/jamiaopen/ooae081 | PMID 39234146 Get It

AbstractObjectivesTo report lessons from integrating the methods and perspectives of clinical informatics (CI) and implementation science (IS) in the context of Improving the Management of symPtoms during and following Cancer Treatment (IMPACT) Consortium pragmatic trials.Materials and MethodsIMPACT informaticists, trialists, and implementation scientists met to identify challenges and solutions by examining robust case examples from 3 Research Centers that are deploying systematic symptom assessment and management interventions via electronic health records (EHRs). Investigators discussed data collection and CI challenges, implementation strategies, and lessons learned.ResultsCI implementation strategies and EHRs systems were utilized to collect and act upon symptoms and impairments in functioning via electronic patient-reported outcomes (ePRO) captured in ambulatory oncology settings. Limited EHR functionality and data collection capabilities constrained the ability to address IS questions. Collecting ePRO data required significant planning and organizational champions adept at navigating ambiguity.DiscussionBringing together CI and IS perspectives offers critical opportunities for monitoring and managing cancer symptoms via ePROs. Discussions between CI and IS researchers identified and addressed gaps between applied informatics implementation and theory-based IS trial and evaluation methods. The use of common terminology may foster shared mental models between CI and IS communities to enhance EHR design to more effectively facilitate ePRO implementation and clinical responses.ConclusionImplementation of ePROs in ambulatory oncology clinics benefits from common understanding of the concepts, lexicon, and incentives between CI implementers and IS researchers to facilitate and measure the results of implementation efforts.
Flow cytometry assay modifications: Recommendations for method validation based on CLSI H62 guidelines
Monaghan, Sara A. , Eck, Steven , Bunting, Silvia T., Dong, Xiangyang X., Durso, Robert J., Gonneau, Christèle , Hays, Amanda , Illingworth, Andrea , League, Stacy C., Linskens, Eleni , McCausland, Megan, McCloskey, Thomas W., Rolf, Nina , Wallace, Paul K. , Litwin, Virginia , Kern, Wolfgang , Deeb, George , Nash, Veronica, Olteanu, Horatiu , Wallace, Paul K , Olteanu, Horatiu , Kern, Wolfgang , Shi, Min

Mayo Clinic

Cytometry Part B: Clinical Cytometry | August 22, 2024 | Volume: 108 | Issue: 3 | Pages: 252-266

10.1002/cyto.b.22202 | PMID 39165120 Get It

AbstractThe Clinical and Laboratory Standards Institute (CLSI) H62—Validation of Assays Performed by Flow Cytometry guideline, released in 2021, provides recommendations for platform workflow and quality system essentials, instrument setup and standardization, assay development and optimization and fit‐for‐purpose analytical method validation. In addition, CLSI H62 includes some recommendations for the validation strategies after a validated flow cytometric method has been modified. This manuscript builds on those recommendations and discusses the impact of different types of assay modifications on assay performance. Recommendations regarding which validation parameters to evaluate depending on the type of modification are provided. The impact of assay modification on the assay's intended use is discussed. When recommending minor deviations from the CLSI H62 process for a laboratory‐initiated assay revision (e.g., specimen numbers for sensitivity, specificity, or precision studies), a rationale based on expert opinion is provided with the understanding that not every laboratory, assay type, and circumstance can be comprehensively addressed in this paper. These recommendations are meant as a practical recommendation and are not intended to be restrictive, prescriptive, or understood as necessarily sufficient to meet every specific requirement from regulatory bodies (e.g., FDA or New York State Department of Health).
Structural Variants at the LMNB1 Locus: Deciphering Pathomechanisms in Autosomal Dominant Adult‐Onset Demyelinating Leukodystrophy
Dimartino, Paola , Zadorozhna, Mariia, Cani, Ilaria , Henck, Jana, Breur, Marjolein , Pippucci, Tommaso , Koufi, Foteini‐Dionysia , Manzoli, Lucia , Delatycki, Martin B. , Vaula, Giovanna , Bugiani, Marianna , Giorgio, Elisa , Brusco, Alfredo , Boschetti, Elisa , Pinto E Vairo, Filippo, Cortelli, Pietro , Giorgio, Elisa , Zadorozhna, Mariia , Yumiceba, Verónica , Basile, Anna, Melo, Uirá Souto , Tonon, Caterina , Lodi, Raffaele , Brusco, Alfredo , Ramazzotti, Giulia , Ratti, Stefano , Vairo, Filippo Pinto e , Cortelli, Pietro , Spielmann, Malte

Mayo Clinic

Annals of Neurology | July 30, 2024 | Volume: 96 | Issue: 5 | Pages: 855-870

10.1002/ana.27038 | PMID 39078102 Get It

ObjectiveWe aimed to elucidate the pathogenic mechanisms underlying autosomal dominant adult‐onset demyelinating leukodystrophy (ADLD), and to understand the genotype/phenotype correlation of structural variants (SVs) in the LMNB1 locus.BackgroundSince the discovery of 3D genome architectures and topologically associating domains (TADs), new pathomechanisms have been postulated for SVs, regardless of gene dosage changes. ADLD is a rare genetic disease associated with duplications (classical ADLD) or noncoding deletions (atypical ADLD) in the LMNB1 locus.MethodsHigh‐throughput chromosome conformation capture, RNA sequencing, histopathological analyses of postmortem brain tissues, and clinical and neuroradiological investigations were performed.ResultsWe collected data from >20 families worldwide carrying SVs in the LMNB1 locus and reported strong clinical variability, even among patients carrying duplications of the entire LMNB1 gene, ranging from classical and atypical ADLD to asymptomatic carriers. We showed that patients with classic ADLD always carried intra‐TAD duplications, resulting in a simple gene dose gain. Atypical ADLD was caused by LMNB1 forebrain‐specific misexpression due to inter‐TAD deletions or duplications. The inter‐TAD duplication, which extends centromerically and crosses the 2 TAD boundaries, did not cause ADLD. Our results provide evidence that astrocytes are key players in ADLD pathology.InterpretationOur study sheds light on the 3D genome and TAD structural changes associated with SVs in the LMNB1 locus, and shows that a duplication encompassing LMNB1 is not sufficient per se to diagnose ADLD, thereby strongly affecting genetic counseling. Our study supports breaking TADs as an emerging pathogenic mechanism that should be considered when studying brain diseases. ANN NEUROL 2024;96:855–870
Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum
Ljungman, Per , Chemaly, Roy F. , Khawaya, Fareed, Badshah, Cyrus, Boeckh, Michael, Fournier, Martha , Hodowanec, Aimee , Komatsu, Takashi , Manuel, Oriol , Pikis, Andreas, Westman, Gabriel , Griffiths, Paul , Kotton, Camille N. , Forum, for the CMV Definitions Working Group of the Transplant Associated Virus Infections, Komatsu, Takashi, Piki, Andreas, Westman, Gabriel, Caliendo, Angie, Chou, Sunwen, Humar, Atul , Wong, Michelle , Wolf, Dana G. , Razonable, Raymund R , Alain, Sophie , Avery, Robin K , Boeckh, Michael , Limaye, Ajit P. , Natori, Yoichiro , Navarro, David , Razonable, Raymund R. , Miller, Veronica , Forum, for the CMV Definitions Working Group of the Transplant Associated Virus Infections, Komatsu, Takashi, Westman, Gabriel, Randhawa, Parmjeet Singh , Slavin, Monica A. , Wong, Michelle

Mayo Clinic

Clinical Infectious Diseases | June 20, 2024 | Volume: 79 | Issue: 3 | Pages: 787-794

10.1093/cid/ciae321 | PMID 39041385 Get It

Abstract Cytomegalovirus (CMV) infection and disease are important causes of morbidity and mortality in transplant recipients. For the purpose of developing consistent reporting of CMV outcomes in clinical trials, definitions of CMV infection and disease were developed and most recently published in 2017. Since then, there have been major developments, including registration of new antiviral agents. Therefore, the Transplant Associated Virus Infections Forum, which consists of scientists, clinicians, regulators, and industry representatives, has produced an updated version of these definitions that incorporates recent knowledge with the aim of supporting clinical research and drug development. This also includes an update regarding the definition of resistant and refractory CMV infections previously published in 2019. As the field evolves, the need for updates of these definitions is clear, and collaborative efforts among clinicians, scientists, regulators, and industry representatives can provide a platform for this work.
Stepwise Functional Brain Architecture Correlates with Atrophy in Progressive Supranuclear Palsy
Spinelli, Edoardo Gioele , Bottale, Ilaria, Basaia, Silvia , Volonté, Maria Antonietta , Prioni, Sara , Villa, Cristina , Josephs, Keith A. , Whitwell, Jennifer L. , Agosta, Federica , Basaia, Silvia , Filippi, Massimo , Agosta, Federica , Ghirelli, Alma , Canu, Elisa , Castelnovo, Veronica , Galantucci, Sebastiano , Magnani, Giuseppe , Caso, Francesca , Cecchetti, Giordano , Caroppo, Paola , Filippi, Massimo

Mayo Clinic

Movement Disorders | June 17, 2024 | Volume: 39 | Issue: 9 | Pages: 1493-1503

10.1002/mds.29887 | PMID 38881298 Get It

Abstract Background Stepwise functional connectivity (SFC) detects whole‐brain functional couplings of a selected region of interest at increasing link‐step topological distances. Objective This study applied SFC to test the hypothesis that stepwise architecture propagating from the disease epicenter would shape patterns of brain atrophy in patients with progressive supranuclear palsy–Richardson's syndrome (PSP‐RS). Methods Thirty‐six patients with PSP‐RS and 44 age‐matched healthy control subjects underwent brain magnetic resonance imaging on a 3‐T scanner. The disease epicenter was defined as the peak of atrophy observed in an independent cohort of 13 cases with postmortem confirmation of PSP pathology and used as seed region for SFC analysis. First, we explored SFC rearrangements in patients with PSP‐RS, as compared with age‐matched control subjects. Subsequently, we tested SFC architecture propagating from the disease epicenter as a determinant of brain atrophy distribution. Results The disease epicenter was identified in the left midbrain tegmental region. Compared with age‐matched control subjects, patients with PSP‐RS showed progressively widespread decreased SFC of the midbrain with striatal and cerebellar regions through direct connections and sensorimotor cortical regions through indirect connections. A correlation was found between average link‐step distance from the left midbrain in healthy subjects and brain volumes in patients with PSP‐RS ( r = 0.38, P < 0.001). Conclusions This study provides comprehensive insights into the topology of functional network rearrangements in PSP‐RS and demonstrates that the brain architectural topology, as described by SFC propagating from the disease epicenter, shapes the pattern of atrophic changes in PSP‐RS. Our findings support the view of a network‐based pathology propagation in this primary tauopathy. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Proactive, automated monitoring of uncontrolled symptoms in prostate cancer survivors across the cancer control continuum.
Muniz, Miguel, Ruddy, Kathryn J. , Grzegorczyk, Veronica , Pachman, Deirdre R. , Cobran, Ewan K. , Loprinzi, Charles L. , Costello, Brian A. , Orme, Jacob J. , Childs, Daniel S. , Morgans, Alicia K. , Griffin, Joan M. , Smith, Ashley Wilder , Kroenke, Kurt , Riaz, Irbaz Bin , Sartor, Oliver , Mitchell, Sandra A , Cheville, Andrea

Mayo Clinic

Journal of Clinical Oncology | June 13, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 12079-12079

10.1200/jco.2024.42.16_suppl.12079 Get It

12079 Background: Many troublesome symptoms experienced by men with prostate cancer are not specific to a particular disease state or treatment modality. As such, these issues' scope is neither fully appreciated nor characterized in the reporting of clinical trial data. A modern accounting of poorly controlled symptoms is needed to better inform survivorship and supportive care efforts. Methods: Data are drawn from the Enhanced, EHR-facilitated Cancer Symptom Control (E2C2) study, a cluster-randomized stepped wedge trial examining the effectiveness of routine symptom assessment and management on patient-centered outcomes and healthcare utilization (NCT03892967). This is a population-level study supporting patients with cancer, who are cared for in medical oncology clinics across the Midwest United States. The trial utilizes an automated symptom monitoring system with EHR-enabled algorithms for symptom triage and intervention. The current analysis focuses on pre-intervention surveys. The cohort includes E2C2 participants with prostate cancer (as determined by the Mayo Clinic Cancer Registry) receiving curative or palliative-intent therapies, along with prostate cancer survivors who previously completed their treatment. The prevalence of SPPADE symptoms (sleep disturbance, pain, impaired physical function, anxiety, depression, fatigue [low energy]) was assessed using 0 to 10 numerical rating scales (NRS), with scores of 4-6 indicating moderate symptoms and 7-10 indicating severe symptoms. Results: A total of 1,388 men with prostate cancer completed a pre-intervention survey between March 2019 and January 2023. The median age at completion of first survey was 74 years. The cohort includes patients living in diverse settings, including urban (n=718, 52%), micropolitan (n=250, 18%), small town (n=218, 16%), and rural (n=200, 14%) environments. The proportion of patients experiencing moderate-to-severe symptoms (NRS score ≥4) was 47% for fatigue, 40% for impaired physical function, 32% for sleep disturbance, 27% for pain, 22% for anxiety, and 20% for depression/emotional distress. The three domains with the highest prevalence of severe symptoms (NRS score ≥7) were fatigue (17%), impaired physical function (12%), and sleep disturbance (10%). Conclusions: Proactive symptom monitoring identifies a high overall burden of moderate-to-severe symptoms, particularly fatigue and impaired physical function, among prostate cancer patients and survivors. Collaborative care approaches and symptom control trials are needed to mitigate and manage these burdensome symptoms. Clinical trial information: NCT03892967 . [Table: see text]